ALPMF - IPO Update: ORIC Pharmaceuticals Readies IPO
Quick Take
ORIC Pharmaceuticals (ORIC) intends to raise $75 million in an IPO of its common stock, per an amended S-1/A registration statement.
The company is advancing a pipeline of drug candidates for the treatment of prostate cancer and solid tumors.
ORIC is led by extremely capable and successful executives in the cancer life science industry, so the IPO may be worth considering for life science investors with a long-term hold time frame.
Company & Technology
South San Francisco, California-based ORIC was founded to develop small molecule antagonists of the glucocorticoid receptor